marketinsights

Breaking Records: Aerojet Rocketdyne Delivers 800th THAAD Boost Motor and Control System

Aerojet Rocketdyne Delivers THAAD’s 800th Boost Motor and Divert and Attitude Control System HUNTSVILLE, Ala., Aug. 10, 2022 (GLOBE NEWSWIRE) — Aerojet Rocketdyne has delivered the 800th Solid Rocket Boost Motor and the 800th Divert and Attitude Control System (DACS) for the Terminal High Altitude Area Defense (THAAD) weapon system. THAAD is one of the…

Read More

Attention Shareholders: Pomerantz Law Firm Launches Investigation into Investor Claims Against U.S. Bancorp (USB)

Attention Shareholders: Pomerantz Law Firm Launches Investigation into Investor Claims Against U.S. Bancorp (USB) Description: NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) – Pomerantz LLP is investigating claims on behalf of investors of U.S. Bancorp (“U.S. Bancorp” or the “Company”) (NYSE: USB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,…

Read More

Unlocking the Benefits of Microdosing: The Launch of a Safe and Regulated Collective for Sub-Perceptible Doses of Psychedelics

New Non-Profit Group Promotes Regulated Use of Sub-Perceptible Psychedelics as Legal Wellness Supplements LOS ANGELES, Aug. 03, 2022 (GLOBE NEWSWIRE) There is a rapidly growing movement to create safe access to psychedelic medicines. As the psychedelic renaissance grows, consumer interest in microdosing psychedelics for wellness is building. The Microdosing Collective (“Microdosing Collective” or “the Collective”)…

Read More

Spain’s July Services PMI Surprises at 53.8, Beating Expectations of 52.0 – A Positive Sign for the Economy!

Spain’s July Services PMI Surprises at 53.8, Beating Expectations of 52.0 – A Positive Sign for the Economy! Description: Prior 54.0Spain’s services sector continues to hold up in July, signaling another expansion with a modest rise in new business. But there are growing concerns about the outlook amid high inflation and economic uncertainty as business…

Read More

Breaking News: FDA Gives Green Light to Coherus’ Cimerli (Ranibizumab EQRN) as the First Interchangeable Biosimilar to Lucentis for All 5 Indications with 12 Months of Interchangeability Exclusivity!

FDA Approves Coherus’ CIMERLI™ Introducing Coherus’ Latest FDA Approved Product Coherus Biosciences, a leading biotechnology company, has received FDA approval for their newest product, CIMERLI™. This marks Coherus’ third FDA-approved product and is the first of four new product launches planned by the end of 2023. The launch of CIMERLI™ is highly anticipated in the…

Read More